|
|
|
|
GenVec Announces Interim Survival Data in Pivotal Trial of TNFerade in Locally Advanced Pancreatic Cancer
Interim Analysis Supports Continuation of GenVec's PACT StudyConference Call Scheduled for Today at 9:00AM GAITHERSBURG, Md.--(HSMN NewsFeed)--GenVec, Inc.(Nasdaq:GNVC ) announced today top-line results of an interim analysis from its...
|
|
|
[REPORTS] Regulation of Pancreatic Cell Mass by Neuronal Signals from the Liver
_ [REPORTS] Regulation of Pancreatic Cell Mass by Neuronal Signals from the Liver.
|
|
|
Data on pancreatic cancer detailed by researchers at Innsbruck Medical University
- (NewsRx.com) -- According to a study from Innsbruck, Austria, 'Pancreatic cancer is one of the most devastating human malignancies (see also Pancreatic Cancer).Despite considerable research efforts, it remains resistant to almost...
|
|
|
Reports summarize pancreatic cancer study results from University of Texas
- (NewsRx.com) -- 'Pancreatic cancer is a major oncological challenge due to its aggressive growth and metastasis (see also Pancreatic Cancer).In the current study, we investigated the role of anterior gradient 2 (AGR2) in these...
|
|
|
New pancreatic cancer study results from AntiCancer, Inc. described
- (NewsRx.com) -- According to recent research from the United States, 'In spite of advances in surgical and medical care, pancreatic cancer remains a leading cause of cancer-related death in the United States (see also Pancreatic...
|
|
|
Learn how to prevent pancreatic cancer
Pancreatic cancer is one you rarely hear about, but it strikes more than 37,000 people in the US every year.Of these, 75 percent will die within a year, and only 4 percent will survive five years. It is the most fatal and least...
|
|
|
TopAbstracts in Pancreatic Cancer 11/19/2008
TopAbstracts in Pancreatic Cancer are the abstracts most highly rated/most read by nearly 300,000 physicians who received a Doctor's Guide newsletter or visited a website Powered by Doctor's Guide in the past 28 days.Over 2000 peer...
|
|
|
Aggressive Surgical Resection in the Management of Pancreatic Neuroendocrine Tumors: When Is It Indicated?
_ Aggressive Surgical Resection in the Management of Pancreatic Neuroendocrine Tumors: When Is It Indicated?.
|
|
|
Borderline Resectable Pancreatic Cancer: On the Edge of Survival
_ Borderline Resectable Pancreatic Cancer: On the Edge of Survival.
|
|
|
The early prediction of mortality in acute pancreatitis: a large population-based study
B U Wu1, R S Johannes1,2, X Sun2, Y Tabak2, D L Conwell1, P A Banks1 1 Brigham and Womens Hospital, Division of Gastroenterology, Center for Pancreatic Disease, Harvard Medical School, Boston Massachusetts, USA 2 Cardinal Health,...
|
|
|
A transgenic mouse model for 'lipid hang-up', or why pathologists need to be involved in genetically engineere
1 Department of Pathology, University Medical Center, Utrecht, The Netherlands 2 Department of Pathology and Oncology, The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins Medical Institutions, Baltimore, Maryland, USA...
|
|
|
Pancreatic cancer has been ignored
I am raising my voice during Pancreatic Cancer Awareness Month.For too long, pancreatic cancer has been ignored; it is the most under-funded, under-recognized and least-studied among leading cancer killers. It might surprise you...
|
|
|
GenVec Announces Interim Survival Data in Pivotal Trial of TNFerade in Locally Advanced Pancreatic Cancer
Interim Analysis Supports Continuation of GenVecs PACT Study Conference Call Scheduled for Today at 9:00AM GAITHERSBURG, Md., Nov.19, 2008--(BUSINESS WIRE)--GenVec, Inc. (Nasdaq:GNVC) announced today top-line results of an interim...
|
|
|
GenVec Announces Interim Survival Data in Pivotal Trial of TNFerade(TM) in Locally Advanced Pancreatic Cancer
Interim Analysis Supports Continuation of GenVec's PACT Study GAITHERSBURG, Md., Nov 19, 2008 (BUSINESS WIRE) -- --Conference Call Scheduled for Today at 9:00AM GenVec, Inc.(GNVC: GNVC News, chart, profile, more Last: Delayed quote data...
|
|
|
GenVec Slides In Pre-Market On Results Of Pancreatic Cancer Drug Study
GenVec (GNVC: ) dropped in pre-market trading, after reporting top-line results of interim analysis from an ongoing phase III pancreatic cancer clinical trial of TNFerade.The stock was down 25 cents just before 8:45 am ET, declining to 90...
|
|
|
GenVec Announces Interim Survival Data in Pivotal Trial of TNFerade in Locally Advanced Pancreatic Cancer
Interim Analysis Supports Continuation of GenVecs PACT Study Conference Call Scheduled for Today at 9:00AM GAITHERSBURG, Md., Nov.19, 2008--(BUSINESS WIRE)--GenVec, Inc. (Nasdaq:GNVC) announced today top-line results of an interim...
|
|
|
GenVec Announces Interim Survival Data in Pivotal Trial of TNFerade in Locally Advanced Pancreatic Cancer
- GenVec, Inc.(Nasdaq:GNVC) announced today top-line results of an interim analysis from its ongoing Phase III Pancreatic Cancer Clinical Trial with TNFerade (PACT) in patients with locally advanced pancreatic cancer. This interim...
|
|
|
GenVec Slides In Pre-Market On Results Of Pancreatic Cancer Drug Study
pre-market trading, after reporting top-line results of interim analysis from an ongoing phase III pancreatic cancer clinical trial of TNFerade.The stock was down 25 cents just before 8:45 am ET, declining to 90 cents. If pre-market...
|
|
|
GenVec Announces Interim Survival Data in Pivotal Trial of TNFerade„in Locally Advanced Pancreatic Can
GenVec, Inc.(Nasdaq:GNVC) announced today top-line results of an interim analysis from its ongoing Phase III Pancreatic Cancer Clinical Trial with TNFerade„ (PACT) in patients with locally advanced pancreatic cancer.
|
|
|
GenVec Announces Interim Survival Data in Pivotal Trial of TNFerade(TM) in Locally Advanced Pancreatic Cancer
GenVec, Inc.(Nasdaq:GNVC) announced today top-line results of an interim analysis from its ongoing Phase III Pancreatic Cancer Clinical Trial with TNFerade(TM) (PACT) in patients with locally advanced pancreatic cancer. This...
|
|
|
GenVec Announces Interim Survival Data in Pivotal Trial of TNFerade in Locally Advanced Pancreatic Cancer
GAITHERSBURG, Md.--(BUSINESS WIRE)--GenVec, Inc.(Nasdaq:GNVC - News) announced today top-line results of an interim analysis from its ongoing Phase III Pancreatic Cancer Clinical Trial with TNFerade (PACT) in patients with locally...
|
|
|
GenVec Announces Interim Survival Data in Pivotal Trial of TNFerade(tm) in Locally Advanced Pancreatic Cancer
-GenVec, Inc.(Nasdaq:GNVC) announced today top-line results of an interim analysis from its ongoing Phase III Pancreatic Cancer Clinical Trial with TNFerade(tm) (PACT) in patients with locally advanced pancreatic cancer. This...
|
|
|
GenVec says interim analysis of trial with TNFerade for locally advanced pancreatic cancer show lower risk of
GenVec, Inc.(GNVC: News ) said that an interim analysis of its Phase III Pancreatic Cancer Clinical Trial with TNFerade, or PACT, in patients with locally advanced pancreatic cancer demonstrated about 25% lower risk of death in the...
|
|
|
GenVec Announces Interim Survival Data in Pivotal Trial of TNFerade(TM) in Locally Advanced Pancreatic Cancer
_ GenVec Announces Interim Survival Data in Pivotal Trial of TNFerade(TM) in Locally Advanced Pancreatic Cancer.
|
|
|
GenVec Announces Interim Survival Data in Pivotal Trial of TNFerade(tm) in Locally Advanced Pancreatic Cancer
_ GenVec Announces Interim Survival Data in Pivotal Trial of TNFerade(tm) in Locally Advanced Pancreatic Cancer.
|
